Modality
mRNA
MOA
C5i
Target
C5
Pathway
Ferroptosis
Myelofibrosis
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
Aug 2018
→ Oct 2027
Phase 2Current
NCT05179843
867 pts·Myelofibrosis
2018-08→2026-04·Active
NCT08590466
1,619 pts·Myelofibrosis
2023-07→2027-10·Recruiting
2,486 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-091w awayPh3 Readout· Myelofibrosis
2027-10-011.5y awayPh3 Readout· Myelofibrosis
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2026-04-09 · 1w away
Myelofibrosis
Ph3 Readout
2027-10-01 · 1.5y away
Myelofibrosis
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05179843 | Phase 2/3 | Myelofibrosis | Active | 867 | PANSS |
| NCT08590466 | Phase 2/3 | Myelofibrosis | Recruiting | 1619 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| HAL-1232 | Halozyme | Approved | C5 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| Olpasotorasib | Structure Ther | Preclinical | C5 |